MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
  • Cardiovascular
  • Orthopedics
  • Wall Street Beat
    • Funding Roundup
    • Mergers & Acquisitions
  • Podcasts
    • MPR: Breakthrough Products Series
  • Resources
    • About MassDevice
    • Newsletter Signup
    • Job Board
    • Leadership in Medtech
    • Manufacturer Search
    • Videos
    • Whitepapers
  • DeviceTalks
You are here: Home / News Well / Rox Medical closes enrollment in hypertension ‘stent’ trial

Rox Medical closes enrollment in hypertension ‘stent’ trial

April 14, 2014 By Brad Perriello Leave a Comment

Rox Medical closes enrollment in hypertension 'stent' trial

Rox Medical said it closed enrollment in a 100-patient clinical trial of its Rox Coupler device, designed to treat hypertension by connecting the femoral artery and the femoral vein.

CEO Rodney Brenneman told MassDevice.com that Rox Medical, a Stanford spinout established in 2004 to pursue several indications including chronic obstructive lung disease and heart failure, noticed a dramatic effect on high blood pressure in COPD patients implanted with the device.

That inspired a small, 8-patient feasibility study to examine the device in hypertensive patients without COPD that delivered "compelling’ results, Brenneman told us.

After the painless, hour-long procedure, "we can hook a pressure transducer up to the arterial line and immediately see a blood pressure drop," he said.

“It’s very repeatable and you know, on the table in the cath lab, that you just achieved the blood pressure drop," he said. "By the time they leave the hospital, the next day – typically in Europe they keep them over 1 night – we’ll measure their blood pressure and they’re already showing a drop, so you basically send someone out the door with an improvement."

Despite the high-profile failure of Medtronic‘s (NYSE:MDT) Symplicity 3 trial, Brenneman said he’s confident there’s a place for an interventional approach to high blood pressure – especially for patients who, for 1 reason or another, can’t control their high blood pressure with drugs.

"Ultimately all the fundamentals are still there, all the things that are interesting about interventional treatments are still there – you still have massive amounts of patients that are unaddressed by poly-pharmacy. I fully expect that renal denervation will be shown to be beneficial for 50% to 70% of patients who get treated; I think it will have a place. At the same time, there’s an issue of time-to-therapy, and the fact that Rox can offer a severe patient an immediate drop in blood pressure is, I think, going to be an extremely compelling story," he said. "The fact that we can be used alongside of any renal denervation therapy and show benefits becomes, I think, very interesting and compelling to everyone with a denervation franchise who might want to add to it. And we’re going to be extremely interesting to those who haven’t entered the market yet, because they don’t have an ablation technology or don’t have a play there. Rox could be extremely interesting to them. We represent a pathway into the U.S. market that arguably many others don’t have without some battle in front of them on the patent front."

Results from the pivotal trial are slated to be released this fall, according to a press release. Brenneman told us that the picture after that, assuming a positive outcome, is likely to involve more trials and limited European commercialization.

"We are preparing a submission for a U.S. trial this year," he said. "Our plan is basically to finish the follow-up on this trial – we should have 6-month data on almost all of these patients by the end of the 3rd quarter, so by late this year we should be presenting the results."

Rox has raised about $55 million in venture capital backing over the past 10 years, undergoing a re-tooling as the VC world consolidated and Rox decided to focus on the hypertension indication, Brenneman said. Initial backers included Versant Ventures, Prism VentureWorks, Domain Assoc. and Essex Woodlands, he told us.

"When we re-focused on hypertension, it was right in the middle of the consolidation of the venture world itself, and although there were a number of dynamics in play there we ended up with kind of a consolidation back to Versant and Domain, moving forward in the hypertension realms, and we shed the Essex Woodlands and Prism investors," he explained. "This has really streamlined the company and the board in a positive way."

Filed Under: News Well Tagged With: Clinical Trials, Hypertension, Rox Medical

In case you missed it

  • Medtronic faces patent lawsuit over CoreValve tech
  • Orpyx launches sensory insoles with patient monitoring
  • Ortho devicemakers Hensler and Tobra face off in patent lawsuit
  • House bill asks CMS to cover breakthrough devices for Medicare patients
  • Empirical Spine completes enrollment in LimiFlex pivotal trial
  • MolecuLight wins FDA clearance for handheld imaging device
  • Medical device tax will cost 20,000 jobs, report says
  • W.L. Gore officials think they can spur insulin delivery system innovation
  • EPA moves closer to stricter regulations on medtech ethylene oxide sterilization
  • 3DBio Therapeutics wins FDA rare pediatric disease designation for outer ear reconstruction
  • CryoLife wins CE Mark for E-nya thoracic stent graft
  • Edwards projects $5 billion in sales for 2020
  • SPR Therapeutics announces 1000th placement of nerve stimulation device
  • The best places to work for medtech sales reps
  • DePuy Synthes issues urgent field safety notice for USS II Polyaxial 3D heads
  • Haemonetics (HAE) launches SafeTrace Tx in North America
  • Vicarious Surgical wins FDA breakthrough designation for surgical robot

RSS From Medical Design & Outsourcing

Leave a Reply Cancel reply

You must be logged in to post a comment.

Need Medtech news in a minute?
We Deliver!

MassDevice Enewsletters get you caught up on all the mission critical news you need in med tech. Sign up today.

Popular Posts

  • Report: SEC probes GE Healthcare, Philips, Siemens in Chinese bribery scheme
  • Edwards Lifesciences warns against below-market mini-tender offer Edwards Lifesciences
  • J&J’s Ethicon files ITC complaint against Intuitive Surgical Intuitive Surgical's EndoWrist instruments
  • Auris Health loses motion to move Intuitive Surgical patent suit from Del. to Cali. Johnson & Johnson's Auris, Intuitive Surgical
  • Enable Injections inks deal with Sanofi for drug delivery platform enfuse-enable-injections
Tweets by @MassDevice
MDO ad

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion

MASSDEVICE

Subscribe to MassDevice
Advertise with us
About
Contact us
Add us on FacebookMassDevice Network
Follow us on Twitter@MassDevice
Connect with us on LinkedInLinkedIn
Follow us on YouTube YouTube

Copyright © 2019 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Advertise | Privacy Policy | RSS